Further to the announcement made on 14 May, Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, presented further details of its Pollinex Quattro Grass Phase III study, G301 atthe European Academy of Allergology and Clinical Immunology meeting on Sunday 8 June 2008. The data was presented by the Lead Investigator of the United Kingdom sites, Professor Anthony Frew, Professor of Allergy and Respiratory Medicine at the Brighton and Sussex Medical School.

Study G301 examined the safety and efficacy of Pollinex Quattro in the treatment of seasonal allergic rhino-conjunctivitis (“SAR”) caused by grass pollen.  G301 was a double-blind, placebo-controlled study comparing the symptom plus medication score of patients given four injections of Pollinex Quattro to those patients receiving placebo.  The trial enrolled 1,028 patients at 84 centres in the United States, Canada and Europe.  The study met its primary efficacy endpoint and demonstrated that Pollinex Quattro has statistically significant clinical benefits over placebo. Furthermore, the data show that the product is effective for both moderate and severe SAR sufferers, is effective during both the peak and the entire pollen season, and improves the quality of life of the patients.

Download full PDF here